Molnupiravir helps stop Sars cov 2, but can cause mutagenesis to your cells | Molnupiravir 有助於阻止 Sars cov 2,但會導致細胞發生突變

Many stduies have already been conducted to understand how Molnupiravir does to stop Sars Cov 2. It is found that the antiviral drug is actually an mutagen (an analog to an essential nucleotide element that is used to make DNA or mRNA) that causes mutagenesis in viral genetics. With this analog inserted into the native genetic sequence, the genetic coding is disrupted, leading to the stoppage of the viral repetition.
The problem is, this drug active ingredient can do the same damage to the human DNA causing mutagenesis and further carcinogensis or causing cancer.  Those who are concerned may read this study for details.
Also watch a video here.

默克公司正在為其抗病毒藥物 Molnupiravir 尋求緊急使用授權。 新聞爆出美國。 政府已經訂購了超過 1000 萬劑。

許多標準研究人員已經開始了解 Molnupiravir 如何阻止 Sars Cov 2。 發現抗病毒藥物實際上是一種誘變劑(一種用於製造 DNA 或 mRNA 的基本核苷酸元件的類似物),會導致病毒遺傳學發生突變 . 將這種類似物插入天然基因序列後,基因編碼被破壞,導致病毒重複停止。

問題是,這種藥物活性成分可以對人類 DNA 造成同樣的損害,導致突變,進而可能致癌或致癌。 有興趣的朋友可以閱讀本研究了解詳情。

β-d-N4-羥基胞苷通過致死誘變抑制 SARS-CoV-2,但對哺乳動物細胞也具有誘變作用。

Gordon CJ, Tchesnokov EP, Schinazi RF, Götte M. J Biol Chem. 2021 Jul;297(1):100770. doi: 10.1016/j.jbc.2021.100770. Epub 2021 May 11. PMID: 33989635 Free PMC article.
Kabinger F, Stiller C, Schmitzová J, Dienemann C, Kokic G, Hillen HS, Höbartner C, Cramer P. Nat Struct Mol Biol. 2021 Sep;28(9):740-746. doi: 10.1038/s41594-021-00651-0. Epub 2021 Aug 11. PMID: 34381216 Free PMC article.
Abdelnabi R, Foo CS, De Jonghe S, Maes P, Weynand B, Neyts J. J Infect Dis. 2021 Sep 1;224(5):749-753. doi: 10.1093/infdis/jiab361. PMID: 34244768 Free PMC article. Clinical Trial.
Zhou S, Hill CS, Sarkar S, Tse LV, Woodburn BMD, Schinazi RF, Sheahan TP, Baric RS, Heise MT, Swanstrom R. J Infect Dis. 2021 Aug 2;224(3):415-419. doi: 10.1093/infdis/jiab247. PMID: 33961695 Free PMC article.
Sheahan TP, Sims AC, Zhou S, Graham RL, Pruijssers AJ, Agostini ML, Leist SR, Schäfer A, Dinnon KH 3rd, Stevens LJ, Chappell JD, Lu X, Hughes TM, George AS, Hill CS, Montgomery SA, Brown AJ, Bluemling GR, Natchus MG, Saindane M, Kolykhalov AA, Painter G, Harcourt J, Tamin A, Thornburg NJ, Swanstrom R, Denison MR, Baric RS. Sci Transl Med. 2020 Apr 29;12(541):eabb5883. doi: 10.1126/scitranslmed.abb5883. Epub 2020 Apr 6. PMID: 32253226 Free PMC article.
Agostini ML, Pruijssers AJ, Chappell JD, Gribble J, Lu X, Andres EL, Bluemling GR, Lockwood MA, Sheahan TP, Sims AC, Natchus MG, Saindane M, Kolykhalov AA, Painter GR, Baric RS, Denison MR. J Virol. 2019 Nov 26;93(24):e01348-19. doi: 10.1128/JVI.01348-19. Print 2019 Dec 15. PMID: 31578288 Free PMC article.
Zhao J, Guo S, Yi D, Li Q, Ma L, Zhang Y, Wang J, Li X, Guo F, Lin R, Liang C, Liu Z, Cen S. Antiviral Res. 2021 Jun;190:105078. doi: 10.1016/j.antiviral.2021.105078. Epub 2021 Apr 21. PMID: 33894278 Free PMC article.
Vicenti I, Zazzi M, Saladini F. Expert Opin Ther Pat. 2021 Apr;31(4):325-337. doi: 10.1080/13543776.2021.1880568. Epub 2021 Mar 3. PMID: 33475441 Free PMC article. Review.
Luo Y, Yu F, Zhou M, Liu Y, Xia B, Zhang X, Liu J, Zhang J, Du Y, Li R, Wu L, Zhang X, Pan T, Guo D, Peng T, Zhang H. mBio. 2021 Jan 19;12(1):e02754-20. doi: 10.1128/mBio.02754-20. PMID: 33468688 Free PMC article.
Page 2

Drug repurposing screens identify chemical entities for the development of COVID-19 interventions.

Bakowski MA, Beutler N, Wolff KC, Kirkpatrick MG, Chen E, Nguyen TH, Riva L, Shaabani N, Parren M, Ricketts J, Gupta AK, Pan K, Kuo P, Fuller M, Garcia E, Teijaro JR, Yang L, Sahoo D, Chi V, Huang E, Vargas N, Roberts AJ, Das S, Ghosh P, Woods AK, Joseph SB, Hull MV, Schultz PG, Burton DR, Chatterjee AK, McNamara CW, Rogers TF. Nat Commun. 2021 Jun 3;12(1):3309. doi: 10.1038/s41467-021-23328-0. PMID: 34083527 Free PMC article.

Page 3

Page 4

Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A.

White KM, Rosales R, Yildiz S, Kehrer T, Miorin L, Moreno E, Jangra S, Uccellini MB, Rathnasinghe R, Coughlan L, Martinez-Romero C, Batra J, Rojc A, Bouhaddou M, Fabius JM, Obernier K, Dejosez M, Guillén MJ, Losada A, Avilés P, Schotsaert M, Zwaka T, Vignuzzi M, Shokat KM, Krogan NJ, García-Sastre A. Science. 2021 Feb 26;371(6532):926-931. doi: 10.1126/science.abf4058. Epub 2021 Jan 25. PMID: 33495306 Free PMC article.

Page 5

Page 6

Precision therapeutic targets for COVID-19.

Krumm ZA, Lloyd GM, Francis CP, Nasif LH, Mitchell DA, Golde TE, Giasson BI, Xia Y. Virol J. 2021 Mar 29;18(1):66. doi: 10.1186/s12985-021-01526-y. PMID: 33781287 Free PMC article. Review.

Page 7

Page 8

SARS-CoV-2 evolution during treatment of chronic infection.

Kemp SA, Collier DA, Datir RP, Ferreira IATM, Gayed S, Jahun A, Hosmillo M, Rees-Spear C, Mlcochova P, Lumb IU, Roberts DJ, Chandra A, Temperton N; CITIID-NIHR BioResource COVID-19 Collaboration; COVID-19 Genomics UK (COG-UK) Consortium, Sharrocks K, Blane E, Modis Y, Leigh KE, Briggs JAG, van Gils MJ, Smith KGC, Bradley JR, Smith C, Doffinger R, Ceron-Gutierrez L, Barcenas-Morales G, Pollock DD, Goldstein RA, Smielewska A, Skittrall JP, Gouliouris T, Goodfellow IG, Gkrania-Klotsas E, Illingworth CJR, McCoy LE, Gupta RK. Nature. 2021 Apr;592(7853):277-282. doi: 10.1038/s41586-021-03291-y. Epub 2021 Feb 5. PMID: 33545711 Free PMC article.

Shotgun transcriptome, spatial omics, and isothermal profiling of SARS-CoV-2 infection reveals unique host responses, viral diversification, and drug interactions.

Butler D, Mozsary C, Meydan C, Foox J, Rosiene J, Shaiber A, Danko D, Afshinnekoo E, MacKay M, Sedlazeck FJ, Ivanov NA, Sierra M, Pohle D, Zietz M, Gisladottir U, Ramlall V, Sholle ET, Schenck EJ, Westover CD, Hassan C, Ryon K, Young B, Bhattacharya C, Ng DL, Granados AC, Santos YA, Servellita V, Federman S, Ruggiero P, Fungtammasan A, Chin CS, Pearson NM, Langhorst BW, Tanner NA, Kim Y, Reeves JW, Hether TD, Warren SE, Bailey M, Gawrys J, Meleshko D, Xu D, Couto-Rodriguez M, Nagy-Szakal D, Barrows J, Wells H, O’Hara NB, Rosenfeld JA, Chen Y, Steel PAD, Shemesh AJ, Xiang J, Thierry-Mieg J, Thierry-Mieg D, Iftner A, Bezdan D, Sanchez E, Campion TR Jr, Sipley J, Cong L, Craney A, Velu P, Melnick AM, Shapira S, Hajirasouliha I, Borczuk A, Iftner T, Salvatore M, Loda M, Westblade LF, Cushing M, Wu S, Levy S, Chiu C, Schwartz RE, Tatonetti N, Rennert H, Imielinski M, Mason CE. Nat Commun. 2021 Mar 12;12(1):1660. doi: 10.1038/s41467-021-21361-7. PMID: 33712587 Free PMC article.

Page 9

AI-guided discovery of the invariant host response to viral pandemics.

Sahoo D, Katkar GD, Khandelwal S, Behroozikhah M, Claire A, Castillo V, Tindle C, Fuller M, Taheri S, Rogers TF, Beutler N, Ramirez SI, Rawlings SA, Pretorius V, Smith DM, Burton DR, Alexander LEC, Duran J, Crotty S, Dan JM, Das S, Ghosh P. EBioMedicine. 2021 Jun;68:103390. doi: 10.1016/j.ebiom.2021.103390. Epub 2021 Jun 11. PMID: 34127431 Free PMC article.

Page 10

Identification of SARS-CoV-2 inhibitors using lung and colonic organoids.

Han Y, Duan X, Yang L, Nilsson-Payant BE, Wang P, Duan F, Tang X, Yaron TM, Zhang T, Uhl S, Bram Y, Richardson C, Zhu J, Zhao Z, Redmond D, Houghton S, Nguyen DT, Xu D, Wang X, Jessurun J, Borczuk A, Huang Y, Johnson JL, Liu Y, Xiang J, Wang H, Cantley LC, tenOever BR, Ho DD, Pan FC, Evans T, Chen HJ, Schwartz RE, Chen S. Nature. 2021 Jan;589(7841):270-275. doi: 10.1038/s41586-020-2901-9. Epub 2020 Oct 28. PMID: 33116299 Free PMC article.

Page 11

The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model.

Abdelnabi R, Foo CS, Kaptein SJF, Zhang X, Do TND, Langendries L, Vangeel L, Breuer J, Pang J, Williams R, Vergote V, Heylen E, Leyssen P, Dallmeier K, Coelmont L, Chatterjee AK, Mols R, Augustijns P, De Jonghe S, Jochmans D, Weynand B, Neyts J. EBioMedicine. 2021 Sep 24;72:103595. doi: 10.1016/j.ebiom.2021.103595. Online ahead of print. PMID: 34571361 Free PMC article.

Letter to the Editor in Response to Zhou et al.

Troth S, Butterton J, DeAnda CS, Escobar P, Grobler J, Hazuda D, Painter G. J Infect Dis. 2021 Jul 12:jiab362. doi: 10.1093/infdis/jiab362. Online ahead of print. PMID: 34251432 Free PMC article. No abstract available.

Reply to Troth et al.

Zhou S, Hill CS, Woodburn BMD, Schinazi RF, Swanstrom R. J Infect Dis. 2021 Jul 13:jiab363. doi: 10.1093/infdis/jiab363. Online ahead of print. PMID: 34255064 Free PMC article. No abstract available.

Covid-19: Molnupiravir reduces risk of hospital admission or death by 50% in patients at risk, MSD reports.

Mahase E. BMJ. 2021 Oct 4;375:n2422. doi: 10.1136/bmj.n2422. PMID: 34607801 No abstract available.

 

$$$ 如果你愿意,你可以在这捐款支持我们。谢谢。$$$
$$$ If you would, you can make a donation here to support us. Thank you. $$$

9

No Responses

Write a response

eleven + nineteen =